AMLODIPINE REDUCES HOSPITALIZATION ASSOCIATED WITH TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH CLINICAL CORONARY ARTERY DISEASE
Author(s)
Chen G, Byington R, Moran M, Department of Public Health Sciences and Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
OBJECTIVE: To examine whether amlodipine can reduce hospitalization associated with treatment of cardiovascular disease (CVD) in patients with angiographic evidence of coronary artery disease. Amlodipine is a long acting calcium channel antagonist that has been proven to be effective in treating cardiovascular diseases. METHOD: We used clinical data derived from the Prospective Randomized Evaluation of Vascular Effects of Norvasc Trial (PREVENT). PREVENT was a 3-year, randomized, masked, placebo-controlled, multicenter, clinical trial originally designed to test the antiatherogenic effect of the calcium channel blocker amlodipine in 825 patients with coronary artery disease (417 patients for amlodipine and 408 patients for placebo). The outcome measures were clinical CVD events associated with hospital care which included congestive heart failure (CHF), myocardial infarction (MI), stroke, angina, coronary artery bypass graft (CABG), percutaneous coronary angioplasty (PTCA), stents, athrectomy, valve replacement, and catheterization. RESULTS: Overall, the net number of hospitalization associated with CVD averted was 27.9 per 100 patients (38.51% reduction) in the amlodipine patient group over three years of the study. Comparing with the placebo group, the treatment group had fewer hospitalizations related to PTCA (-11.75 per 100 patients, 52.69% reduction), CABG (-3.03, 42.62% reduction), stent (-2.02, 41.22% reduction), angina (-9.27, 31.52% reduction), and CHF (-2.46, 91.11% reduction). There were no significant impacts on hospital utilization related to stroke (-0.03 per 100 patients), valve replacement (0.48) and fatal MI (0.13). CONCLUSION: In this study, amlodipine is found to be an effective agent in reducing hospital utilization related to CVD, especially CHF, PTCA, CABG, stent, and angina, in patients with clinical coronary artery disease relative to the placebo. Further analysis will examine whether amlodipine can reduce hospital care costs associated with CVD.
Conference/Value in Health Info
1999-11, ISPOR Europe 1999, Edinburgh, Scotland
Value in Health, Vol. 2, No. 5 (September/October1999)
Code
CV7
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders